GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oragenics Inc (AMEX:OGEN) » Definitions » Shiller PE Ratio

Oragenics (Oragenics) Shiller PE Ratio : (As of Jun. 08, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Oragenics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Oragenics Shiller PE Ratio Historical Data

The historical data trend for Oragenics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oragenics Shiller PE Ratio Chart

Oragenics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Oragenics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Oragenics's Shiller PE Ratio

For the Biotechnology subindustry, Oragenics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oragenics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oragenics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Oragenics's Shiller PE Ratio falls into.



Oragenics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Oragenics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Oragenics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.7/131.7762*131.7762
=-0.700

Current CPI (Mar. 2024) = 131.7762.

Oragenics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -30.000 100.560 -39.313
201409 -18.000 100.428 -23.619
201412 -18.000 99.070 -23.942
201503 -24.000 99.621 -31.747
201506 -102.000 100.684 -133.499
201509 -30.000 100.392 -39.379
201512 -36.000 99.792 -47.538
201603 -30.000 100.470 -39.348
201606 -6.000 101.688 -7.775
201609 -24.000 101.861 -31.048
201612 -34.200 101.863 -44.243
201703 -24.000 102.862 -30.746
201706 -15.000 103.349 -19.126
201709 -25.200 104.136 -31.889
201712 -18.000 104.011 -22.805
201803 -25.200 105.290 -31.539
201806 -22.800 106.317 -28.260
201809 -21.000 106.507 -25.982
201812 -5.617 105.998 -6.983
201903 -6.600 107.251 -8.109
201906 -6.000 108.070 -7.316
201909 -4.800 108.329 -5.839
201912 -4.800 108.420 -5.834
202003 -6.600 108.902 -7.986
202006 -14.400 108.767 -17.446
202009 -4.800 109.815 -5.760
202012 -3.000 109.897 -3.597
202103 -3.000 111.754 -3.537
202106 -1.800 114.631 -2.069
202109 -2.400 115.734 -2.733
202112 -0.890 117.630 -0.997
202203 -2.290 121.301 -2.488
202206 -1.850 125.017 -1.950
202209 -1.990 125.227 -2.094
202212 -0.900 125.222 -0.947
202303 -1.410 127.348 -1.459
202306 -1.510 128.729 -1.546
202309 -0.850 129.860 -0.863
202312 -5.480 129.419 -5.580
202403 -0.700 131.776 -0.700

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Oragenics  (AMEX:OGEN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Oragenics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Oragenics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Oragenics (Oragenics) Business Description

Traded in Other Exchanges
Address
4902 Eisenhower Boulevard, Suite 125, Tampa, FL, USA, 33634
Oragenics Inc is engaged in research and the development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. Its product (NT-CoV2-1) is an intranasal vaccine candidate to prevent coronavirus disease ("COVID-19") from the SARS-CoV-2 virus and variants thereof. Its focus on developing vaccines and novel antibiotics It is also developing a Terra CoV-2 immunization product candidate to combat the novel coronavirus.
Executives
Fred Telling director 501 ELLIOTT AVE. W., SUITE 400, SEATTLE WA 98119
John P Gandolfo director 62 TERRACE ROAD, WAYNE NJ 07470
Cassidy Bruce A. Sr. director C/O LOOP MEDIA, 700 N CENTRAL AVENUE, SUITE 430, GLENDALE CA 91203
Janet Huffman officer: CFO, Secretary and Treasurer 5317 FRUITVILLE RD SUITE 6, SARASOTA FL 34232
Robert C Koski director, 10 percent owner 1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243
Michael O'keefe Sullivan officer: CFO, Secretary and Treasurer 3000 BAYPORT DRIVE, SUITE 685, TAMPA FL 33607
Joseph Hernandez 10 percent owner C/O MICROLIN BIO, INC., NEW YORK NY 10022
Kimberly M Murphy director 101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Koski Family Lp 10 percent owner 1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243
Randal J Kirk 10 percent owner 1881 GROVE AVENUE, RADFORD VA 24141
Alan Joslyn director, officer: CEO and President 39 OLD RIDGEBURY ROAD, DANBURY CT 06810
Charles L Pope director 4902 EISENHOWER BOULEVARD, TAMPA FL 33634
Christine L Koski director, 10 percent owner 1500 WEST UNIVERSITY PARKWAY, SARASOTA FL 34243
Beverly Koski 10 percent owner
Thomas L Koski 10 percent owner

Oragenics (Oragenics) Headlines

From GuruFocus